CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to NVO

insulin human

Phase 3
Novo Nordisk A/S (NVO)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

14

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Diabetes

Clinical Trial

NCT00071448

Last updated: 12/18/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Insulin Human 30/70 Mix Marvel

View on EMA
EMAPending

Insulin Human Rapid Marvel

View on EMA
EMAPending

Insulin Human Long Marvel

View on EMA
EMAPending

Combimarv

Treatment of diabetes mellitus

View on EMA
EMAPending

Solumarv

treatment of diabetes mellitus

View on EMA
EMAPending

Isomarv medium

treatment of diabetes mellitus

View on EMA
EMA1/17/2007

Insulin Human Winthrop

Diabetes mellitus where treatment with insulin is required. Insulin Human Winthrop Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.

View on EMA
EMA10/7/2002

Ultratard

Treatment of diabetes mellitus.

View on EMA
EMA10/7/2002

Velosulin

Treatment of diabetes mellitus.

View on EMA
EMA10/7/2002

Actraphane

Treatment of diabetes mellitus.

View on EMA
EMA10/7/2002

Mixtard

Treatment of diabetes mellitus.

View on EMA
EMA10/7/2002

Protaphane

Treatment of diabetes mellitus.

View on EMA
EMA10/7/2002

Monotard

Treatment of diabetes mellitus.

View on EMA
EMA10/7/2002

Insulatard

Treatment of diabetes mellitus.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.